Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hemodialysis Patients
78%
Hemodialysis
47%
Peritoneal Dialysis
42%
Far-infrared Therapy
36%
Chronic Kidney Disease
32%
Peritoneal Dialysis Patients
29%
Arteriovenous Fistula
29%
Vascular Access
28%
Taiwan
26%
Maintenance Hemodialysis Patients
22%
Patency
20%
Hazard Ratio
16%
Uremic Patients
14%
Dialysis
14%
Heme oxygenase-1 (HO-1)
13%
Arteriovenous Graft
13%
Risk Factors
13%
Acrolein
13%
National Cohort Study
13%
Randomized Controlled Trial
13%
Diabetic Kidney Disease
13%
Asymmetric Dimethylarginine
12%
Hemodialysis Vascular Access
12%
Continuous Erythropoietin Receptor Activator
12%
End-stage Renal Disease
11%
Clinical Outcomes
11%
Erythropoiesis-stimulating Agents
11%
Kidney Fibrosis
11%
Arteriovenous Fistula Patency
10%
Proteinuria
10%
Peritoneal Dialysis Catheter Insertion
10%
Dialysis Membrane
10%
95% Confidence Interval
10%
Hematocrit
10%
Kidney Disease
10%
Kidney Function
9%
Aldehyde Dehydrogenase 2 (ALDH2)
9%
Retrospective Cohort Study
9%
Dialysis Patients
8%
Yoga
8%
COVID-19
8%
High Risk
8%
Perfluorohexane Sulfonate (PFHxS)
8%
Atrial Fibrillation
8%
Far-infrared
8%
Genotype
7%
Hypoglycemia
7%
Mitochondrial Dysfunction
7%
Vascular Thrombosis
7%
Hypertension
7%
Medicine and Dentistry
Hemodialysis
100%
Peritoneal Dialysis
59%
Vascular Access
41%
Arteriovenous Fistula
33%
Heat Therapy
32%
Chronic Kidney Disease
30%
End Stage Renal Disease
22%
Prevalence
12%
Diabetes Mellitus
11%
Dialysis Catheter
10%
Hazard Ratio
10%
Proteinuria
10%
Randomized Controlled Trial
9%
Yoga
9%
Thrombosis
9%
N(g),n(g) Dimethylarginine
9%
Nephrology
9%
Blood Pressure
9%
Creatinine
9%
Cardiovascular System
8%
Nephropathy
8%
Cohort Analysis
7%
Glomerulonephritis
7%
Cohort Effect
7%
Prognostic Factor
7%
Kidney Function
7%
ACE Inhibitor
7%
Apoplexy
7%
Urinary System
7%
Cardiovascular Disease
7%
Immunosuppressant
7%
Ankle Brachial Index
6%
Hypoglycemia
6%
Pneumocystis Pneumonia
6%
Polycystic Kidney Disease
6%
Nodular Goiter
6%
Thyroid Disease
6%
Angiotensin Receptor Antagonist
6%
Heme Oxygenase 1
6%
Infection
5%
Renin Angiotensin Aldosterone System
5%
Therapeutic Modality
5%
Quality of Life
5%
Health Care Cost
5%
Retrospective Cohort Study
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
83%
Arteriovenous Fistula
22%
Inflammation
16%
Acrolein
16%
Cohort Study
15%
End Stage Renal Disease
14%
Chronic Kidney Failure
13%
Coronavirinae
13%
Congestive Heart Failure
13%
Continuous Erythropoiesis Receptor Activator
12%
Diabetic Nephropathy
11%
Diseases
10%
Aldehyde Dehydrogenase Isoenzyme 2
9%
Diabetes Mellitus
9%
Coronary Artery Disease
9%
Atrial Fibrillation
8%
Creatinine
8%
Perfluorooctanesulfonic Acid
8%
C Reactive Protein
8%
Hypertension
8%
Cardiovascular Disease
8%
Infection
7%
Acute Kidney Failure
7%
Dipeptidyl Carboxypeptidase Inhibitor
7%
Cerebrovascular Accident
7%
Angiotensin Receptor Antagonist
6%
Pathophysiology
6%
Lipid
6%
Randomized Controlled Trial
6%
6 N,n' Dimethylarginine
6%
N(g),n(g) Dimethylarginine
6%
Dipeptidyl Peptidase IV Inhibitor
6%
Valsartan/Sacubitril
6%
Heme Oxygenase 1
6%
Glucose
6%
Kidney Disease
5%
Angiotensin
5%
Renin
5%
Heart Failure with Reduced Ejection Fraction
5%
Anemia
5%
Brain Ischemia
5%
